Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.
- NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_assertion description "[Treatment of metastatic disease has improved significantly with the addition of several new agents, including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and yttrium-90-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and lutetium-177-DOTA octreotate.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.
- NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_assertion evidence source_evidence_literature NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.
- NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_assertion SIO_000772 21388967 NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.
- NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_assertion wasDerivedFrom befree-20140225 NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.
- NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_assertion wasGeneratedBy ECO_0000203 NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.
- befree-20140225 importedOn "2014-02-25" NP613564.RAtbGyE1exVks-1ajAwcZ_8LYvsqgHKSZdReAnTuCMhMM130_provenance.